ClinicalTrials.gg
Not yet recruitingNCT07857564PIT-PLPDUpdated Oct 26, 2026

Iodine Starch Test Use in Pleuroperitoneal Leak

An interventional study of Iodine tincture in Peritoneal Dialysis, Peritoneal Dialysis (PD) and Pleural Cavity Effusion, sponsored by Nottingham University Hospitals NHS Trust. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Nottingham University Hospitals NHS Trust · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a study to see how a simple test can be used to check if fluid in the chest cavity contains starch. Some people with kidney failure have dialysis treatment by putting fluid in the tummy cavity, and sometimes the fluid can leak into the chest cavity. Iodine can change the colour of starch based dialysis fluid, so this test could be used to diagnose fluid leaking from the tummy cavity into the chest cavity. The investigators are doing this study to ensure the fluid doesn't change colour for other reasons.

Read the detailed description

This is a study involving adult patients who are already undergoing a pleural fluid drainage procedure as part of their routine clinical care. The study is based on the results of a laboratory proof of principle experiment which the investigators performed in the NUH BioResource and Research \& Innovation Laboratory in November 2025, using non-clinical samples of standard peritoneal dialysis fluid to determine how much and what type of iodine is able to differentiate icodextrin from glucose or amino acid based peritoneal dialysis fluids. This has allowed the investigators to determine a clinical test in order to undertake an study of both non-dialysis patients who present to the pleural clinic (controls) and patients on peritoneal dialysis presenting with effusions to the renal unit, to ensure the iodine starch can be used in practice and that the test does not produce false positive results in patients with pleural effusions of other causes. The investigators will perform a control study in order to ensure that false positive results do not occur in pleural effusions of other causes. The investigators will consent 15 patients undergoing diagnostic or therapeutic pleural aspiration in the NUH pleural clinic. The sample size is an estimate based on the typical incidence of different pleural fluid types obtained in the NUH pleural clinic, and is expected to be sufficient to ensure we obtain samples of transudative, exudative and blood-stained effusion samples. The investigators will concurrently perform an study of patients on peritoneal dialysis who undergo diagnostic pleural aspiration (usually to investigate a possible pleuroperitoneal leak). The investigators will recruit five patients on peritoneal dialysis who present with pleural effusion to the Renal Home Therapies Unit. Up to five patients on peritoneal dialysis will also be recruited from two other UK centres. Potential participants will be identified by their usual clinical team when they attend the pleural clinic or renal service for a planned diagnostic or therapeutic pleural aspiration. Participants will consent for the investigators to collect 20mL of pleural fluid that is surplus to that required for clinical purposes. This will not require any changes to practice as it is standard clinical practice to remove larger volumes of fluid to relieve patients symptoms, and discard the waste fluid. The investigators add the pre-determined volume of Iodine and potassium iodide 2% (0.1mL) to 10mL of pleural fluid. The investigators will photograph the samples in the BioResource and Research \& Innovation Laboratory using a standard iPhone camera on an NUH provided work iPhone, and then discard the samples. The remaining 10mL will be frozen at -80oCin the BioResource and Research \& Innovation Laboratory to allow comparison of samples taken at different times, and reproducibility verification or collaborative validation with the other two renal units in the UK. Frozen samples will be kept for 2 years.

Following consent patients will be allocated a study number and pseudonomysed for completion of CRF. The investigators will collect demographic data (age, sex) and relevant past medical history (chronic kidney disease, chronic obstructive pulmonary disease, diabetes, heart failure, ischaemic heart disease, hypertension)from each recruit, results of biochemical tests conducted in NUH laboratories as part of their standard care, and diagnostic information.

Based on the outcome of the clinical study and the background laboratory studies the investigators will be able to validate recommendations about the volume and type of iodine needed to identify the presence of icodextrin in a pleural aspiration sample, which were demonstrated in the laboratory experiment.

02

Conditions studied

  • Peritoneal Dialysis
  • Peritoneal Dialysis (PD)
  • Pleural Cavity Effusion
  • Hydrothorax

Browse trials for

Keywords

  • Peritoneal dialysis
  • Icodextrin
  • Pleuroperitoneal leak
  • Pleural effusion
  • Hydrothorax
03

In context

Pleural Effusion

241 studies on the registry are indexed under Pleural Effusion; 49 are open to participants now.

This study's planned enrollment of 30 is below the median of 80 across 142 interventional studies indexed under Pleural Effusion.

Browse Pleural Effusion studies →

Lead sponsor

Nottingham University Hospitals NHS Trust is the lead sponsor of 107 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (aged ≥18 years) attending for diagnostic or therapeutic pleural aspiration.
  • Able and willing to provide written for use of a small surplus pleural fluid sample for research purposes.
  • Sufficient pleural fluid volume (demonstrated on routine pre-procedure thoracic ultrasound scan) available to allow safe collection of at least an additional 10 mL sample without affecting routine clinical testing (clinical samples would require a minimum of 10mLs but common clinical practice is to remove larger volumes in in order to allow symptomatic relief).

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age.
  • Unable to give (e.g. due to cognitive impairment or lack of capacity).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Observational

    Observation

    Diagnostic Test: Iodine tincture

Interventions

  • Diagnostic testIodine tincture

    Iodine and potassium iodide 2% (0.1mL)

06

What researchers measure

Primary outcomes

  1. False positive results of iodine-starch test (blue-black colour change) when applied to pleural fluid samples from non-dialysis patients on a single sample at baseline

    To assess whether the iodine-starch test produces any false positive results when applied to pleural fluid samples from non-dialysis patients on a single sample at baseline.

    Time frame: Baseline

  2. Positive Iodine-starch test (blue black colour change) in the pleural fluid of patients with a pleuroperitoneal leak using Icodextrin, on single baseline pleural fluid sample

    To assess whether the iodine-starch test can be used in practice to positively identify icodextrin in the pleural fluid of patients with a pleuroperitoneal leak on a single baseline pleural fluid sample.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Observational study only

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 61 non-industry interventional studies with no phase under Pleural Effusion, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 52. This study's planned 12 months is below that.

Counting every sponsor, half of 63 studies reached it within 26 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 5, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 2 updates
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857564
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Jennifer C Allen, BMBS PHD
Contact
jennifer.allen36@nhs.net
+44 01159627678

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion